A new strategy to estimate levothyroxine requirement after total thyroidectomy and radioiodine remnant ablation for 'intermediate' and 'high' risk differentiated thyroid cancer

2017 ◽  
Author(s):  
Rosa Maria Paragliola ◽  
Rosa Annapina De ◽  
Donna Vincenzo Di ◽  
Giampaolo Papi ◽  
Alfredo Pontecorvi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
High Risk ◽  
Total Thyroidectomy ◽  
Differentiated Thyroid Cancer ◽  
Remnant Ablation ◽  
New Strategy ◽  
Radioiodine Remnant Ablation

Impact of earlyvslate postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer

2013 ◽  
Vol 80 (3) ◽  
pp. 459-463 ◽  
Author(s):  
Sofia Tsirona ◽  
Varvara Vlassopoulou ◽  
Marinella Tzanela ◽  
Phoebe Rondogianni ◽  
George Ioannidis ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Final Outcome ◽  
Low Risk ◽  
Remnant Ablation ◽  
Well Differentiated ◽  
Radioiodine Remnant Ablation

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdrawal

Thyroid ◽  
2014 ◽  
Vol 24 (3) ◽  
pp. 480-487 ◽  
Author(s):  
Peter Bartenstein ◽  
Elisa Caballero Calabuig ◽  
Carlo Ludovico Maini ◽  
Renzo Mazzarotto ◽  
M. Angustias Muros de Fuentes ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
High Risk ◽  
Differentiated Thyroid Cancer ◽  
Primary Tumors ◽  
Remnant Ablation ◽  
Thyroid Hormone Withdrawal ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Undetectable thyroglobulin makes 123I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: a retrospective study

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Bastiaan Sol ◽  
Bert Bravenboer ◽  
Brigitte Velkeniers ◽  
Steven Raeymaeckers ◽  
Marleen Keyaerts ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Differentiated Thyroid Cancer ◽  
Whole Body ◽  
Whole Body Scan ◽  
Body Scan ◽  
Remnant Ablation ◽  
Follow Up Care ◽  
Prognostic Utility

Abstract Background Differentiated thyroid cancer (DTC) is a common malignancy with increasing incidence. Follow-up care for DTC includes thyroglobulin (Tg) measurement and ultrasound (US) of the neck, combined with 131I remnant ablation when indicated. Diagnostic precision has evolved with the introduction of the new high-sensitive Tg-assays (sensitivity ≤0.1 ng/mL). The aim of the study was to determine the prognostic utility of high-sensitive Tg and the need for other diagnostic tests in DTC. Methods This was a retrospective, observational study. Patients with pathologically confirmed DTC, treated with total thyroidectomy and 131I remnant ablation, who had their complete follow-up care in our institution were selected (October 2013–December 2018). Subjects with possible thyroglobulin autoantibody interference were excluded. Statistical analysis was performed using the IBM SPSS® Statistics 24 software package. Results Forty patients were eligible for analysis. A total of 24 out of the 40 patients (60%) had an undetectable high-sensitive Tg 6 months after total thyroidectomy. None of these patients had a stimulated Tg above 1 ng/mL, or remnant on the 123I Whole-Body Scan (WBS) after 1 year of follow-up. Ultrasound of the neck, performed between 6 and 12 months postoperative, was negative in 21 out of the 24 patients. Conclusions This study shows that an undetectable high-sensitive Tg can change the management of patients with DTC and decrease the use and need of stimulated Tg and 123I WBS.

Sign in / Sign up

Export Citation Format

Share Document